Home > Oncology > ASCO 2021 > Breast Cancer > Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases

Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases

Presented By
Prof. Guy Jerusalem , CHU Liège, Belgium
Conference
ASCO 2021
Trial
Phase 2, DESTINY-Breast01
A subgroup analysis of the DESTINY-Breast01 trial demonstrated clinical activity of the antibody-drug conjugate trastuzumab-deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer who presented with baseline brain metastases. Patients with HER2-positive metastatic breast cancer are at high risk of developing brain metastases, and treatment options are limited once brain metastases occur [1]. T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor payload [2]. In the ongoing, phase 2 DESTINY-Breast01 trial (NCT03248492), 184 patients with HER2-positive metastatic breast cancer were enrolled, of whom 24 had a history of brain metastases (17 had brain lesions at baseline). Patients received T-DXd at 5.4 mg/kg every 3 we...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on